Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Holan LIANG |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Acceptability and feasibility of a parent-mediated social-communication therapy for young autistic children in Brazil: A qualitative implementation study of Paediatric Autism Communication Therapy / Lorna MCWILLIAMS ; Leticia RODRIGUES DA SILVEIRA ; Mirian DE CESARO REVERS BIASÃO ; Fernanda SPEGGIORIN PEREIRA ALARCÃO ; Leonardo SEDA ; Renata GENEROSO CAMPOLI ; Holan LIANG ; Gauri DIVAN ; Kathy LEADBITTER in Autism, 28-1 (January 2024)
[article]
Titre : Acceptability and feasibility of a parent-mediated social-communication therapy for young autistic children in Brazil: A qualitative implementation study of Paediatric Autism Communication Therapy Type de document : Texte imprimé et/ou numérique Auteurs : Lorna MCWILLIAMS, Auteur ; Leticia RODRIGUES DA SILVEIRA, Auteur ; Mirian DE CESARO REVERS BIASÃO, Auteur ; Fernanda SPEGGIORIN PEREIRA ALARCÃO, Auteur ; Leonardo SEDA, Auteur ; Renata GENEROSO CAMPOLI, Auteur ; Holan LIANG, Auteur ; Gauri DIVAN, Auteur ; Kathy LEADBITTER, Auteur Article en page(s) : p.123?137 Mots-clés : autism Brazil implementation study Paediatric Autism Communication Therapy qualitative study Index. décimale : PER Périodiques Résumé : Effective support for autistic individuals is lacking in Brazil. Few centres offer services and those that do are limited in therapeutic options and geographical location. Paediatric Autism Communication Therapy is a low-intensity, evidence-based parent-mediated social-communication intervention that may be useful for this scenario. This implementation study aimed to assess the acceptability and feasibility of Paediatric Autism Communication Therapy for young autistic children (aged 2?10?years) in Brazil. Parents (n?=?18) of 2- to 10-year-old autistic children and clinicians (n?=?20) who work with autistic children in Brazil were interviewed and the data analysed using thematic analysis to explore their perceptions concerning the acceptability and feasibility of Paediatric Autism Communication Therapy. In addition, Paediatric Autism Communication Therapy was delivered to a case series of 15 further parent?child dyads; these parents were interviewed at the end of the therapy, and the data were analysed using thematic analysis. All parents and clinicians had favourable opinions about the acceptability, feasibility and perceived effectiveness of a parent-mediated intervention conducted mainly in the home. However, they also highlighted obstacles concerning the implementation of Paediatric Autism Communication Therapy in Brazil, especially related to engaging Brazilian parents in a parent-mediated model of therapy. Based on these data, minor adaptations were made to the original Paediatric Autism Communication Therapy protocol to facilitate the implementation of the intervention in Brazil. Lay abstract Parents of autistic children and health professionals who work with autistic children in Brazil had positive views about introducing Paediatric Autism Communication Therapy as a therapy for autistic children in Brazil. The parents and clinicians also mentioned some difficulties about using Paediatric Autism Communication Therapy in Brazil. We made adaptations to Paediatric Autism Communication Therapy to address these difficulties. Paediatric Autism Communication Therapy is a therapy to support the development of social and communication skills for autistic children aged 2?10 years. The therapy is conducted with the autistic child?s parent. Paediatric Autism Communication Therapy has not been used in Brazil before. There are few therapy options available for autistic children in Brazil and we believed that Paediatric Autism Communication Therapy may be useful. We asked three groups of people in Brazil about their views of Paediatric Autism Communication Therapy, after explaining how the therapy works. Group 1 included 18 parents of autistic children aged 2?10 years. Group 2 included 20 health professionals such as psychologists who work with autistic children. Group 3 included 15 parents of autistic children aged 2?7 years who received the Paediatric Autism Communication Therapy. We learned that parents and clinicians felt that Paediatric Autism Communication Therapy would be a beneficial therapy for autistic children in Brazil. We also found out about the challenges of using Paediatric Autism Communication Therapy in Brazil. We used these findings to make small cultural adaptations to Paediatric Autism Communication Therapy to make it more suitable for Brazil. En ligne : https://dx.doi.org/10.1177/13623613221144501 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=519
in Autism > 28-1 (January 2024) . - p.123?137[article] Acceptability and feasibility of a parent-mediated social-communication therapy for young autistic children in Brazil: A qualitative implementation study of Paediatric Autism Communication Therapy [Texte imprimé et/ou numérique] / Lorna MCWILLIAMS, Auteur ; Leticia RODRIGUES DA SILVEIRA, Auteur ; Mirian DE CESARO REVERS BIASÃO, Auteur ; Fernanda SPEGGIORIN PEREIRA ALARCÃO, Auteur ; Leonardo SEDA, Auteur ; Renata GENEROSO CAMPOLI, Auteur ; Holan LIANG, Auteur ; Gauri DIVAN, Auteur ; Kathy LEADBITTER, Auteur . - p.123?137.
in Autism > 28-1 (January 2024) . - p.123?137
Mots-clés : autism Brazil implementation study Paediatric Autism Communication Therapy qualitative study Index. décimale : PER Périodiques Résumé : Effective support for autistic individuals is lacking in Brazil. Few centres offer services and those that do are limited in therapeutic options and geographical location. Paediatric Autism Communication Therapy is a low-intensity, evidence-based parent-mediated social-communication intervention that may be useful for this scenario. This implementation study aimed to assess the acceptability and feasibility of Paediatric Autism Communication Therapy for young autistic children (aged 2?10?years) in Brazil. Parents (n?=?18) of 2- to 10-year-old autistic children and clinicians (n?=?20) who work with autistic children in Brazil were interviewed and the data analysed using thematic analysis to explore their perceptions concerning the acceptability and feasibility of Paediatric Autism Communication Therapy. In addition, Paediatric Autism Communication Therapy was delivered to a case series of 15 further parent?child dyads; these parents were interviewed at the end of the therapy, and the data were analysed using thematic analysis. All parents and clinicians had favourable opinions about the acceptability, feasibility and perceived effectiveness of a parent-mediated intervention conducted mainly in the home. However, they also highlighted obstacles concerning the implementation of Paediatric Autism Communication Therapy in Brazil, especially related to engaging Brazilian parents in a parent-mediated model of therapy. Based on these data, minor adaptations were made to the original Paediatric Autism Communication Therapy protocol to facilitate the implementation of the intervention in Brazil. Lay abstract Parents of autistic children and health professionals who work with autistic children in Brazil had positive views about introducing Paediatric Autism Communication Therapy as a therapy for autistic children in Brazil. The parents and clinicians also mentioned some difficulties about using Paediatric Autism Communication Therapy in Brazil. We made adaptations to Paediatric Autism Communication Therapy to address these difficulties. Paediatric Autism Communication Therapy is a therapy to support the development of social and communication skills for autistic children aged 2?10 years. The therapy is conducted with the autistic child?s parent. Paediatric Autism Communication Therapy has not been used in Brazil before. There are few therapy options available for autistic children in Brazil and we believed that Paediatric Autism Communication Therapy may be useful. We asked three groups of people in Brazil about their views of Paediatric Autism Communication Therapy, after explaining how the therapy works. Group 1 included 18 parents of autistic children aged 2?10 years. Group 2 included 20 health professionals such as psychologists who work with autistic children. Group 3 included 15 parents of autistic children aged 2?7 years who received the Paediatric Autism Communication Therapy. We learned that parents and clinicians felt that Paediatric Autism Communication Therapy would be a beneficial therapy for autistic children in Brazil. We also found out about the challenges of using Paediatric Autism Communication Therapy in Brazil. We used these findings to make small cultural adaptations to Paediatric Autism Communication Therapy to make it more suitable for Brazil. En ligne : https://dx.doi.org/10.1177/13623613221144501 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=519 Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability / Emily SIMONOFF in Journal of Child Psychology and Psychiatry, 54-5 (May 2013)
[article]
Titre : Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability Type de document : Texte imprimé et/ou numérique Auteurs : Emily SIMONOFF, Auteur ; Eric TAYLOR, Auteur ; Gillian BAIRD, Auteur ; Sarah BERNARD, Auteur ; Oliver CHADWICK, Auteur ; Holan LIANG, Auteur ; Susannah WHITWELL, Auteur ; Kirsten RIEMER, Auteur ; Kishan SHARMA, Auteur ; Santvana Pandey SHARMA, Auteur ; Nicky WOOD, Auteur ; Joanna KELLY, Auteur ; Ania GOLASZEWSKI, Auteur ; Juliet KENNEDY, Auteur ; Lydia RODNEY, Auteur ; Nicole WEST, Auteur ; Rebecca WALWYN, Auteur ; Fatima JICHI, Auteur Article en page(s) : p.527-535 Langues : Anglais (eng) Mots-clés : Attention deficit disorder with hyperactivity Randomized controlled trial autism mental retardation intellectual disability methylphenidate stimulants Index. décimale : PER Périodiques Résumé : Background: Attention deficit hyperactivity disorder is increased in children with intellectual disability. Previous research has suggested stimulants are less effective than in typically developing children but no studies have titrated medication for individual optimal dosing or tested the effects for longer than 4 weeks. Method: One hundred and twenty two drug-free children aged 7–15 with hyperkinetic disorder and IQ 30–69 were recruited to a double-blind, placebo-controlled trial that randomized participants using minimization by probability, stratified by referral source and IQ level in a one to one ratio. Methylphenidate was compared with placebo. Dose titration comprised at least 1 week each of low (0.5 mg/kg/day), medium (1.0 mg/kg/day) and high dose (1.5 mg/kg/day). Parent and teacher Attention deficit hyperactivity disorder (ADHD) index of the Conners Rating Scale-Short Version at 16 weeks provided the primary outcome measures. Clinical response was determined with the Clinical Global Impressions scale (CGI-I). Adverse effects were evaluated by a parent-rated questionnaire, weight, pulse and blood pressure. Analyses were by intention to treat. Trial registration: ISRCTN 68384912. Results: Methylphenidate was superior to placebo with effect sizes of 0.39 [95% confidence intervals (CIs) 0.09, 0.70] and 0.52 (95% CIs 0.23, 0.82) for the parent and teacher Conners ADHD index. Four (7%) children on placebo versus 24 (40%) of those on methylphenidate were judged improved or much improved on the CGI. IQ and autistic symptoms did not affect treatment efficacy. Active medication was associated with sleep difficulty, loss of appetite and weight loss but there were no significant differences in pulse or blood pressure. Conclusions: Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability. Adverse effects typical of methylphenidate were seen and medication use may require close monitoring in this vulnerable group. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2012.02569.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=196
in Journal of Child Psychology and Psychiatry > 54-5 (May 2013) . - p.527-535[article] Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability [Texte imprimé et/ou numérique] / Emily SIMONOFF, Auteur ; Eric TAYLOR, Auteur ; Gillian BAIRD, Auteur ; Sarah BERNARD, Auteur ; Oliver CHADWICK, Auteur ; Holan LIANG, Auteur ; Susannah WHITWELL, Auteur ; Kirsten RIEMER, Auteur ; Kishan SHARMA, Auteur ; Santvana Pandey SHARMA, Auteur ; Nicky WOOD, Auteur ; Joanna KELLY, Auteur ; Ania GOLASZEWSKI, Auteur ; Juliet KENNEDY, Auteur ; Lydia RODNEY, Auteur ; Nicole WEST, Auteur ; Rebecca WALWYN, Auteur ; Fatima JICHI, Auteur . - p.527-535.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 54-5 (May 2013) . - p.527-535
Mots-clés : Attention deficit disorder with hyperactivity Randomized controlled trial autism mental retardation intellectual disability methylphenidate stimulants Index. décimale : PER Périodiques Résumé : Background: Attention deficit hyperactivity disorder is increased in children with intellectual disability. Previous research has suggested stimulants are less effective than in typically developing children but no studies have titrated medication for individual optimal dosing or tested the effects for longer than 4 weeks. Method: One hundred and twenty two drug-free children aged 7–15 with hyperkinetic disorder and IQ 30–69 were recruited to a double-blind, placebo-controlled trial that randomized participants using minimization by probability, stratified by referral source and IQ level in a one to one ratio. Methylphenidate was compared with placebo. Dose titration comprised at least 1 week each of low (0.5 mg/kg/day), medium (1.0 mg/kg/day) and high dose (1.5 mg/kg/day). Parent and teacher Attention deficit hyperactivity disorder (ADHD) index of the Conners Rating Scale-Short Version at 16 weeks provided the primary outcome measures. Clinical response was determined with the Clinical Global Impressions scale (CGI-I). Adverse effects were evaluated by a parent-rated questionnaire, weight, pulse and blood pressure. Analyses were by intention to treat. Trial registration: ISRCTN 68384912. Results: Methylphenidate was superior to placebo with effect sizes of 0.39 [95% confidence intervals (CIs) 0.09, 0.70] and 0.52 (95% CIs 0.23, 0.82) for the parent and teacher Conners ADHD index. Four (7%) children on placebo versus 24 (40%) of those on methylphenidate were judged improved or much improved on the CGI. IQ and autistic symptoms did not affect treatment efficacy. Active medication was associated with sleep difficulty, loss of appetite and weight loss but there were no significant differences in pulse or blood pressure. Conclusions: Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability. Adverse effects typical of methylphenidate were seen and medication use may require close monitoring in this vulnerable group. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2012.02569.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=196